Flecainide: A New Class Ic Antidysrhythmic

  title={Flecainide: A New Class Ic Antidysrhythmic},
  author={G. H. Smith},
  booktitle={Drug intelligence \& clinical pharmacy},
  • G. Smith
  • Published in
    Drug intelligence & clinical…
    1 October 1985
  • Medicine, Biology
Flecainide acetate is a new orally active antidysrhythmic agent classified in the Ic category. Flecainide is effective in suppressing 88 to 100 percent of abnormal cardiac rhythms in the form of complex ventricular dysrhythmias, including couplets, ventricular tachycardia, reentrant junctional tachycardia, and Wolff-Parkinson-White syndrome. Flecainide appears to have a greater effect on conduction than on repolarization and only minimal effects on hemodynamic parameters. Flecainide is rapidly… 

Figures and Tables from this paper

New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.

Multiple targets for flecainide action: implications for cardiac arrhythmogenesis

Anti‐arrhythmic effects of flecainide that reduce triggering in CPVT models mediated by sarcoplasmic reticular Ca2+ release could arise from its primary actions on Nav channels indirectly decreasing [Ca2+]i through a reduced [Na+] i and/or direct open‐state RyR2‐Ca2- channel antagonism.

Bio-analytical method development and validation of Flecainide by Liquid-liquid extraction with LC-MS / MS : by application to a pharmacokinetic study

  • Medicine, Biology
  • 2017
It has high bioavailability after an oral dose with plasma half-life is about 20 hours with Peak serum concentrations can be seen 1 to 6 hours after ingestion of an oral dose. [1-2]. During oral

Polymorphism of human cytochrome P450 enzymes and its clinical impact

Current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) is highlighted to understand the large interindividual variability in drug clearance and responses in clinical practice and to improve the efficacy and safety of both prospective and currently available drugs.



Electrophysiologic properties of flecainide acetate.

Antiarrhythmic effects of flecainide

  • P. Somani
  • Medicine, Biology
    Clinical pharmacology and therapeutics
  • 1980
A new class I antiarrhythmic, flecainide, was investigated in 10 patients to assess short‐term efficacy and safety and did not induce significant changes in P‐R, QRS, or Q‐T intervals.

Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans.

The drug's relatively long plasma half-life in humans indicates that plasma levels will be maintained for prolonged periods; thus flecainide should provide sustained therapeutic activity in patients with cardiac arrhythmias.

Suppression of Ventricular Ectopic Depolarizations by Flecainide Acetate, A New Antiarrhythmic Agent

Flecainide acetate was given orally to 11 hospitalized patients with chronic high-frequency ventricular ectopic depolarizations to indicate that flecainides is a very effective antiarrhythmic agent that merits further clinical investigation.

Oral flecainide acetate for the treatment of ventricular arrhythmias.

Fleckcainide appears to be a highly effective and well-tolerated antiarrhythmic agent with favorable pharmacokinetics.